In Reply We thank Gros et al for their interest and their thoughtful comments on our article.1 In response, we described monoamine oxidase B inhibitors (MAOBIs) and catechol-O-methyltransferase inhibitors (COMTIs) as dopamine degradation inhibitors in the PD MED protocol. This was amended during the article review process to dopamine reuptake inhibitors. We have no strong views on best terminology; the key point in the trial design was that these 2 classes of drug were, and remain, the main alternatives to dopamine agonists as adjuvant treatment for motor complications that are unresponsive to levodopa dose escalation.
Gray R, Jenkinson C, Clarke CE. Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply. JAMA Neurol. 2022;79(7):726–727. doi:10.1001/jamaneurol.2022.1604
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.